Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Op. Gr: Emer. COVID Res. Gaps/Prior- Dif. Impacts on Hist. Excl/Underserved Pops

Unity Health Toronto

$499,302.00

Ab-C Risk: Action to Beat Coronavirus Sub-study on Population Immunity in High-Risk Groups in Canada

EF 2021-22

Résumé
We have been studying the impact of SARS-CoV-2 infection and vaccination on immunity among a representative sample of about 20,000 Canadian adults, in the Action to Beat Coronavirus in Canada (Ab-C) study, since early in the pandemic. Ab-C Risk will recruit an additional 1,000 Canadians belonging to higher risk demographic and ethnic groups. The Ab-C cohort was recruited in collaboration with the Angus Reid Institute, which will continue to lead in surveying participants periodically about COVID-related experiences, including infection, clinical signs and symptoms, exposures, PCR testing for the virus (including variants of concern), and vaccination. Ab-C relies on participants to self-collect finger prick blood samples on special paper, and send them to Unity Health for analysis for SARS-CoV-2 antibodies. Three rounds of surveys and blood samples have been completed. A fourth and fifth round, planned into 2022, will include the new Ab-C Risk cohort. The main Ab-C Risk research questions are: 1. What are the levels of SARS-CoV-2 vaccine-induced and natural immunity among VIPs compared with other groups? 2. How does persistence of SARS-CoV-2 antibodies among VIPs compare with other groups? 3. Can we identify age-specific predictors of maintained and declining SARS-CoV-2 antibodies among VIPs compared with others? After each Phase, Ab-C publishes for a professional audience in high-impact journals, and for the public in a variety of forms, including Ab-C newsletters and interviews with the Canadian press. We plan to add video releases to be widely distributed to planners and others working with VIPs. The Ab-C team, from six Canadian research institutions and the Angus Reid Institute, combines experience in large-scale population epidemiology, demography and biostatistics, laboratory science, clinical infectious disease, Indigenous health, health economics and priority setting, health equity, IT, communications, and knowledge translation.
Programme
Op. Gr: Emer. COVID Res. Gaps/Prior- Dif. Impacts on Hist. Excl/Underserved Pops
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
459214
Name
Jha Prabhat
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Operating Grant: Emerging COVID-19 Research Gaps & Priorities (July 2021)
Projecttitle
Ab-C Risk: Action to Beat Coronavirus Sub-study on Population Immunity in High-Risk Groups in Canada
Programtype2
Operating Grants
Orgnameinp2
Unity Health Toronto
Cihramount2
$499,302
Cihrequipment2
$0
Programname2
Op. Gr: Emer. COVID Res. Gaps/Prior- Dif. Impacts on Hist. Excl/Underserved Pops
Keyworddelim
Determinants Of Risk; Epidemiology; National Antibody Study; Risk Among Vunerable Canadians
Abstract
We have been studying the impact of SARS-CoV-2 infection and vaccination on immunity among a representative sample of about 20,000 Canadian adults, in the Action to Beat Coronavirus in Canada (Ab-C) study, since early in the pandemic. Ab-C Risk will recruit an additional 1,000 Canadians belonging to higher risk demographic and ethnic groups. The Ab-C cohort was recruited in collaboration with the Angus Reid Institute, which will continue to lead in surveying participants periodically about COVID-related experiences, including infection, clinical signs and symptoms, exposures, PCR testing for the virus (including variants of concern), and vaccination. Ab-C relies on participants to self-collect finger prick blood samples on special paper, and send them to Unity Health for analysis for SARS-CoV-2 antibodies. Three rounds of surveys and blood samples have been completed. A fourth and fifth round, planned into 2022, will include the new Ab-C Risk cohort. The main Ab-C Risk research questions are: 1. What are the levels of SARS-CoV-2 vaccine-induced and natural immunity among VIPs compared with other groups? 2. How does persistence of SARS-CoV-2 antibodies among VIPs compare with other groups? 3. Can we identify age-specific predictors of maintained and declining SARS-CoV-2 antibodies among VIPs compared with others? After each Phase, Ab-C publishes for a professional audience in high-impact journals, and for the public in a variety of forms, including Ab-C newsletters and interviews with the Canadian press. We plan to add video releases to be widely distributed to planners and others working with VIPs. The Ab-C team, from six Canadian research institutions and the Angus Reid Institute, combines experience in large-scale population epidemiology, demography and biostatistics, laboratory science, clinical infectious disease, Indigenous health, health economics and priority setting, health equity, IT, communications, and knowledge translation.
Competitiondate
202109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jha, Prabhat
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $499,302~ $0~